Jonathon Cohen, MD, Discusses Treatment Options and Prognosis in MCL

Image removed.At the 2018 Lymphoma & Myeloma congress held in New York, Jonathon Cohen, MD, MS, Assistant Professor, Lymphoma Group, Winship Cancer Institute, Emory University, Atlanta, Georgia, spoke to Oncology Learning Network about varying treatment options for patients with mantle cell lymphoma, as well as methods available to help prognosticate a patient's response to certain treatments.

Check out the 3-part video series with Dr Cohen below!


Obinutuzumab vs Rituximab for Patients With Lymphoma

Jonathon Cohen, MD, provides insight on whether obinutuzumab or rituximab is a more appropriate treatment option for patients with lymphoma.

Watch Here


Prognostic Markers for Therapy Selection in Mantle Cell Lymphoma

Jonathon Cohen, MD, discusses the Mantle Cell Lymphoma International Prognostic Index (MIPI), the Ki-67 proliferative index, and various molecular assessments that can be informative in determining which patients will benefit from specific therapies.

Watch Here


Treating Relapsed Mantle Cell Lymphoma

Jonathon Cohen, MD, discusses a number of therapies available for the treatment of relapsed mantle cell lymphoma. 

Watch Here


Stay in the know.
OncNet Newsletter